Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALVAC(2) melanoma vaccine in metastatic melanoma
NCT00613509Phase 2Terminated
- Sponsor
- Sanofi
- Start
- Jun 2008
- Primary completion
- Apr 2010
- Modality
- Viral Vector Vaccines
- Countries
- 2
01
Overview
A Phase 2 trial of ALVAC(2) melanoma multi-antigen therapeutic vaccine in melanoma, sponsored by Sanofi. Started Jun 2008; status: terminated.
02
Drugs
ALVAC(2) melanoma multi-antigen therapeutic vaccine
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00613509.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00613509.